SCHEMBL209296

SCHEMBL209296

Clc1ccc2[c]nccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
NR4A2 P43354 2/20 0.35
NOS1 P29475 2/20 0.35
F7 P08709 2/20 0.33
F3 P13726 2/20 0.33
HTR2B P41595 1/20 0.33
PDE4D Q08499 1/20 0.33
LTA4H P09960 1/20 0.33
AHR P35869 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
TP53 P04637 1/20 0.32
DYRK1A Q13627 2/20 0.31
HTR3A P46098 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
F11 P03951 1/20 0.31
PIK3CG P48736 1/20 0.31
ALDH1A1 P00352 1/20 0.30
CYP3A4 P08684 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208536 0.85 NR4A2 (0.38) CYP2A6NR4A2NOS1HTR2BPDE4D
SCHEMBL29119722 0.77 PLAU (0.41) CYP2A6TP53HTR3AALDH1A1CYP3A4
SCHEMBL206447 0.77 BACE1 (0.38) CYP2A6NR4A2NOS1AHRDYRK1A
SCHEMBL206485 0.77 BACE1 (0.38) CYP2A6AHRPDE3BPDE3A
SCHEMBL2356812 0.77 CYP1A2 (0.42) CYP2A6NOS1PDE3BPDE3AALDH1A1
SCHEMBL15512056 0.72 ALDH1A1 (0.35) ALDH1A1ALOX15TSHRTDP1
SCHEMBL207876 0.72 HDAC8 (0.34)
SCHEMBL577971 0.72 RAB9A (0.46) CYP2A6ALDH1A1CYP3A4SMN1; SMN2PDGFRB
SCHEMBL577942 0.71 BACE1 (0.38)
SCHEMBL2080 0.70 ALDH1A1 (0.35) CYP2A6NOS1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925611-B1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO CO LTD (JP) 2016-04-13 EP disclosed
CN-103214414-B The diamine derivative of opticity and manufacture method thereof SANKYO CO. (JP) 2016-02-17 CN disclosed
CN-103214414-A Optically active diamine derivative and process for producing the same DAIICHI SANKYO CO LTD 2013-07-24 CN disclosed
EP-2431370-B1 Monoacylated 1,2-diaminocycloalkanes DAIICHI SANKYO CO LTD (JP) 2013-06-19 EP disclosed
CN-101263110-B Optically active diamine derivative and process for producing the same DAIICHI SANKYO CO LTD 2013-04-03 CN disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
CN-102002059-B Process for producing thiazole derivative DAIICHI SANKYO CO LTD 2012-06-13 CN disclosed
EP-2431370-A1 Monoacylated 1,2-diaminocycloalkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2012-03-21 EP disclosed
CN-101914107-B Process for producing thiazole derivative DAIICHI SEIYAKU CO 2012-03-07 CN disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
CN-1438993-A Ethylenediamine derivatives DAIICHI SEIYAKU CO (JP) 2003-08-27 CN disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020645-A1 Diamine derivatives C9, C1S, C1R CYP2A6 2751/4885NR4A2 3125/4885NOS1 151/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R CYP2A6 2751/4885NR4A2 3125/4885NOS1 151/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R CYP2A6 2751/4885NR4A2 3125/4885NOS1 151/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 CYP2A6 1405/4885NR4A2 1317/4885NOS1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.